当前位置: X-MOL 学术Nat. Cancer › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Targeting public neoantigens for cancer immunotherapy
Nature Cancer ( IF 23.5 ) Pub Date : 2021-05-17 , DOI: 10.1038/s43018-021-00210-y
Alexander H Pearlman 1, 2, 3 , Michael S Hwang 1, 2, 3, 4 , Maximilian F Konig 1, 2, 3, 5 , Emily Han-Chung Hsiue 1, 2, 3 , Jacqueline Douglass 1, 2, 3 , Sarah R DiNapoli 1, 2, 3 , Brian J Mog 1, 2, 3, 6 , Chetan Bettegowda 1, 2, 7, 8 , Drew M Pardoll 8, 9 , Sandra B Gabelli 8, 10, 11 , Nicholas Papadopoulos 1, 2, 9, 12, 13 , Kenneth W Kinzler 1, 2, 8, 9, 13 , Bert Vogelstein 1, 2, 3, 8, 9, 12, 13 , Shibin Zhou 1, 2, 8, 9
Affiliation  

Several current immunotherapy approaches target private neoantigens derived from mutations that are unique to individual patients’ tumors. However, immunotherapeutic agents can also be developed against public neoantigens derived from recurrent mutations in cancer driver genes. The latter approaches target proteins that are indispensable for tumor growth, and each therapeutic agent can be applied to numerous patients. Here we review the opportunities and challenges involved in the identification of suitable public neoantigen targets and the development of therapeutic agents targeting them.



中文翻译:


针对癌症免疫治疗的公共新抗原



目前的几种免疫治疗方法针对的是源自个体患者肿瘤特有的突变的私人新抗原。然而,免疫治疗剂也可以针对源自癌症驱动基因反复突变的公共新抗原而开发。后者针对的是肿瘤生长所必需的靶蛋白,并且每种治疗剂都可以应用于众多患者。在这里,我们回顾了确定合适的公共新抗原靶点以及开发针对这些靶点的治疗药物所涉及的机遇和挑战。

更新日期:2021-05-18
down
wechat
bug